SG11201507404RA - Compositions and methods of using islet neogenesis peptides and analogs thereof - Google Patents

Compositions and methods of using islet neogenesis peptides and analogs thereof

Info

Publication number
SG11201507404RA
SG11201507404RA SG11201507404RA SG11201507404RA SG11201507404RA SG 11201507404R A SG11201507404R A SG 11201507404RA SG 11201507404R A SG11201507404R A SG 11201507404RA SG 11201507404R A SG11201507404R A SG 11201507404RA SG 11201507404R A SG11201507404R A SG 11201507404RA
Authority
SG
Singapore
Prior art keywords
analogs
compositions
methods
islet neogenesis
peptides
Prior art date
Application number
SG11201507404RA
Other languages
English (en)
Inventor
Liping Liu
Ru Bai
Original Assignee
Shenzhen Hightide Biopharmaceutical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Hightide Biopharmaceutical Ltd filed Critical Shenzhen Hightide Biopharmaceutical Ltd
Publication of SG11201507404RA publication Critical patent/SG11201507404RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4733—Acute pancreatitis-associated protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201507404RA 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof SG11201507404RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2013/072771 WO2014139182A1 (en) 2013-03-15 2013-03-15 Compositions and methods of using islet neogenesis peptides and analogs thereof
PCT/CN2014/073483 WO2014139472A1 (en) 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof

Publications (1)

Publication Number Publication Date
SG11201507404RA true SG11201507404RA (en) 2015-10-29

Family

ID=51535856

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507404RA SG11201507404RA (en) 2013-03-15 2014-03-14 Compositions and methods of using islet neogenesis peptides and analogs thereof

Country Status (14)

Country Link
US (7) US20160039877A1 (pt)
EP (2) EP2970385B1 (pt)
JP (2) JP6674258B2 (pt)
KR (1) KR102244349B1 (pt)
AU (3) AU2014231444B2 (pt)
BR (1) BR112015022469A2 (pt)
CA (1) CA2906240C (pt)
ES (1) ES2703110T3 (pt)
IL (1) IL241383B (pt)
MX (2) MX2015012038A (pt)
NZ (1) NZ711958A (pt)
RU (1) RU2685958C2 (pt)
SG (1) SG11201507404RA (pt)
WO (2) WO2014139182A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4560952B2 (ja) * 1999-12-03 2010-10-13 株式会社セガ ゲーム装置及びゲームシステム
JP2016508509A (ja) * 2013-02-15 2016-03-22 ザ・ロイヤル・インスティテューション・フォア・ジ・アドヴァンスメント・オブ・ラーニング／マックギル・ユニバーシティＴｈｅ Ｒｏｙａｌ Ｉｎｓｔｉｔｕｔｉｏｎ Ｆｏｒ Ｔｈｅ Ａｄｖａｎｃｅｍｅｎｔ Ｏｆ Ｌｅａｒｎｉｎｇ／Ｍｃｇｉｌｌ Ｕｎｉｖｅｒｓｉｔｙ 糖尿病を治療するための改変されたｉｎｇａｐペプチド
EP3413917A4 (en) * 2016-02-10 2019-09-11 Pfizer Inc THERAPEUTIC NANOPARTICLES COMPRISING EGFR LIGANDS AND METHODS OF MAKING AND USING SAME
CN108616978B (zh) * 2016-12-14 2022-04-15 中兴通讯股份有限公司 一种网络功能实体进行无状态处理的方法及装置
KR102006890B1 (ko) * 2016-12-27 2019-08-05 한양대학교 산학협력단 췌장 소도 세포 표적 펩타이드 및 이의 용도
US10772929B2 (en) 2017-05-11 2020-09-15 Shenzhen Hightide Biopharmaceutical, Ltd. Use of peptide compounds in treating acute pancreatitis
US20190142901A1 (en) * 2017-11-16 2019-05-16 Claresa Levetan Compositions and methods for treating or preventing type 1 diabetes using a biologic response modifier in combination with one or more islet or beta cell regeneration or replacement therapies
CN113307845B (zh) * 2018-09-18 2022-05-24 广州领晟医疗科技有限公司 促进肝细胞增殖和/或抑制肝细胞凋亡的多肽及其用途
EP4143305A2 (en) * 2020-05-01 2023-03-08 The Broad Institute, Inc. Engineered central nervous system compositions
WO2023143446A1 (en) * 2022-01-25 2023-08-03 Shenzhen Hightide Biopharmaceutical Ltd. Compositions and methods for treating cytokine storm

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
FR2700011B1 (fr) 1992-12-24 1995-02-24 Inst Nat Sante Rech Med Détection de la mucoviscidose ou d'une mutation du gêne CFTR au moyen d'un dosage de la PAP.
JP3532566B2 (ja) 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
DE69434594T2 (de) 1993-10-25 2006-09-21 Canji, Inc., San Diego Rekombinante adenoviren-vektor und verfahren zur verwendung
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US5834590A (en) 1995-02-22 1998-11-10 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Ingap protein involved in pancreatic islet neogenesis
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5804421A (en) 1996-10-30 1998-09-08 Eastern Virginia Medical School Of The Medical College Fo Hampton Roads High level of expression of ingap in bacterial and euraryotic cells
US5935813A (en) 1997-03-20 1999-08-10 Incyte Pharmaceuticals, Inc. Human pancreatitis-associated protein
US20020052308A1 (en) 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20040018623A1 (en) 1999-10-29 2004-01-29 Lawrence Rosenberg Medium for preparing dedifferentiated cells
US20020009730A1 (en) 1999-11-17 2002-01-24 Alex Chenchik Human stress array
CA2343602A1 (en) 2000-04-18 2001-10-18 Genset Est's and encoded human proteins
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
DE10056802B4 (de) 2000-11-14 2005-06-16 Epigenomics Ag Verfahren zur Detektion von Methylierungszuständen zur toxikologischen Diagnostik
AU2156802A (en) 2000-12-13 2002-06-24 Borean Pharma As Combinatorial libraries of proteins having the scaffold structure of c-type lectin-like domains
US20040018970A1 (en) 2000-12-19 2004-01-29 Shimkets Richard A. Novel nucleic acids and polypeptides and methods of use thereof
WO2002059315A2 (en) 2000-12-19 2002-08-01 Curagen Corporation Human nucleic acids and polypeptides and methods of use thereof
US6986994B2 (en) 2001-01-09 2006-01-17 Gmp Endotherapeutics, Inc. INGAP displacement assays
US20040158036A1 (en) 2001-03-01 2004-08-12 Lawrence Rosenberg Neuritogenic compound and uses thereof
EP1478772A2 (en) 2001-08-14 2004-11-24 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
IL160289A0 (en) 2001-08-30 2004-07-25 Biorexis Pharmaceutical Corp Modified transferrin fusion proteins
US20040132644A1 (en) * 2001-10-16 2004-07-08 The Procter & Gamble Company Composition and method for treating diabetes
EP1578385A4 (en) 2001-10-19 2011-11-09 Genentech Inc COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF INFLAMMATORY INTESTINAL DISEASES
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
US7662768B2 (en) 2002-01-11 2010-02-16 Mcgill University Transdifferentiation of pancreatic acinar cells
US7166439B2 (en) 2002-03-01 2007-01-23 Gmp Endotherapeutics, Inc. Assay for anti-INGAP antibodies
US20070015271A1 (en) 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
AU2003241388A1 (en) 2002-05-09 2003-11-11 Medtronic Minimed, Inc. Immunoprotective methods for beta cell neogenesis
US20040018522A1 (en) 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
EP1523577A2 (en) 2002-07-10 2005-04-20 Oncotherapy Science, Inc. Method for diagnosis of intestinal-type gastric tumors
JP2004065120A (ja) 2002-08-07 2004-03-04 Sumitomo Pharmaceut Co Ltd 炎症性腸疾患の疾患マーカー及びその利用
EP1539221B1 (en) 2002-08-30 2009-12-23 Biorexis Pharmaceutical Corporation Transferrin fusion protein libraries
AU2003275853A1 (en) 2002-10-24 2004-05-13 Mcgill University Use of ingap for reversing diabetes
US20040219572A1 (en) 2002-12-17 2004-11-04 Jie Chen Specific markers for pancreatic cancer
US7510708B2 (en) 2003-04-14 2009-03-31 Washington University Disruption of the REG pathway
EP1488798A1 (en) 2003-06-18 2004-12-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) HIP/PAP polypeptide composition for use in liver regeneration and for the prevention of liver failure
WO2005113812A2 (en) 2004-04-23 2005-12-01 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20050277593A1 (en) 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
BRPI0511069A (pt) 2004-06-04 2007-11-27 Wyeth Corp inibidores de proteìnas regiii como terapêutica para asma
KR100639677B1 (ko) 2004-11-08 2006-10-30 삼성전자주식회사 위상 및 지연 동기 루프와 이를 구비한 반도체 메모리 장치
KR100664586B1 (ko) 2004-12-22 2007-01-04 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
CA2726759C (en) * 2005-05-25 2016-02-16 Curedm Group Holdings, Llc Human proislet peptide, derivatives and analogs thereof, and methods of using same
HUE045165T2 (hu) 2005-08-19 2019-12-30 Amylin Pharmaceuticals Llc Exendin diabetes kezelésére és testtömeg csökkentésére
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
WO2007056511A2 (en) 2005-11-09 2007-05-18 Ontherix, Inc. Metal-binding therapeutic peptides
US20080039393A1 (en) 2005-11-09 2008-02-14 Desmond Mascarenhas Metal-binding therapeutic peptides
WO2007071437A2 (en) 2005-12-22 2007-06-28 Ares Trading S.A. Compositions and methods for treating inflammatory disorders
WO2008011518A2 (en) 2006-07-19 2008-01-24 Diakine Therapeutics, Inc. Encapsulation system
KR20060089873A (ko) 2006-07-25 2006-08-09 김현기 인간 원암 유전자, 이에 의해 코드되는 단백질, 이를포함하는 발현벡터 및 이 벡터로 형질 전환된 세포
EP2057465A4 (en) 2006-08-09 2010-04-21 Homestead Clinical Corp SPECIFIC ORGAN PROTEINS AND METHODS OF USE
CA2667476A1 (en) 2006-11-02 2008-07-17 Genizon Biosciences Inc. Genemap of the human genes associated with asthma disease
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
WO2008079406A2 (en) 2006-12-19 2008-07-03 Genentech, Inc. Gene expression markers for inflammatory bowel disease
FR2910311B1 (fr) 2006-12-20 2009-02-13 Oreal Composition comprenant un compose silicone et un organosilane particulier
US7923014B2 (en) 2007-02-12 2011-04-12 The Board Of Regents Of The University Of Texas System Expression and purification of HIP/PAP and uses therefor
BRPI0809423A2 (pt) 2007-03-26 2014-09-09 Salutria Pharmaceuticals Llc Usos e composições de derivados de probucol para o tratamento de diabetes
US20080280985A1 (en) 2007-03-27 2008-11-13 Scott Robert A D Methods and Compositions Using Certain Phenolic Derivatives for the Treatment of Diabetes
EP2570431A3 (en) * 2007-08-30 2013-05-01 CureDM Group Holdings, LLC Compositions and methods of using proislet peptides and analogs thereof
WO2009049222A1 (en) 2007-10-12 2009-04-16 Curedm, Inc. Compositions and methods of using the human proislet peptide receptor
WO2009062102A2 (en) 2007-11-07 2009-05-14 Genentech, Inc. Compositions and methods for treatment of microbial disorders
AU2008334095A1 (en) 2007-11-29 2009-06-11 Genentech, Inc. Gene expression markers for inflammatory bowel disease
US20100004213A1 (en) 2007-11-29 2010-01-07 Abbas Alexander R Gene expression markers for inflammatory bowel disease
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
US20100331248A1 (en) 2008-01-31 2010-12-30 Diakine Therapeutics, Inc. Compositions and methods for treating diabetes using lisofylline and islet neogenesis associated peptide
EP2257814B1 (en) 2008-03-21 2012-08-29 Podiceps B.v. Diagnostic of pre-symptomatic metabolic syndrome
MX2011003117A (es) 2008-09-19 2011-04-21 Nektar Therapeutics Conjugados polimericos de peptidos terapeuticos.
JP2010085375A (ja) 2008-10-02 2010-04-15 Nationa Hospital Organization 細胞増殖を伴う糖尿病合併症の検査のための方法、組成物およびキット
WO2010062663A1 (en) 2008-11-03 2010-06-03 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US8012928B2 (en) 2008-12-19 2011-09-06 The Research Foundation Of State University Of New York Truncated PAP2 and methods of making and using same
EP2393828B1 (en) 2009-02-03 2016-10-12 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
EP2260857A1 (en) 2009-06-11 2010-12-15 Alfact Innovation Novel applications of HIP/PAP or derivatives thereof
ES2356217B1 (es) 2009-08-04 2012-02-13 Universidad De Salamanca Método para la detección de daño renal.
CA2776954A1 (en) 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial libraries based on c-type lectin domain
WO2011043835A1 (en) 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that bind il-23r
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
ES2374370B1 (es) 2010-08-04 2013-01-08 Universidad De Salamanca Método para la detección de daño renal.
CN102827253B (zh) * 2011-06-17 2017-07-21 上海市第一人民医院 一种抑制炎症反应的小分子多肽及其应用
JP2016508509A (ja) * 2013-02-15 2016-03-22 ザ・ロイヤル・インスティテューション・フォア・ジ・アドヴァンスメント・オブ・ラーニング／マックギル・ユニバーシティＴｈｅ Ｒｏｙａｌ Ｉｎｓｔｉｔｕｔｉｏｎ Ｆｏｒ Ｔｈｅ Ａｄｖａｎｃｅｍｅｎｔ Ｏｆ Ｌｅａｒｎｉｎｇ／Ｍｃｇｉｌｌ Ｕｎｉｖｅｒｓｉｔｙ 糖尿病を治療するための改変されたｉｎｇａｐペプチド

Also Published As

Publication number Publication date
KR102244349B1 (ko) 2021-04-23
AU2014231444A1 (en) 2015-10-01
US20220348618A1 (en) 2022-11-03
RU2685958C2 (ru) 2019-04-23
US10899815B2 (en) 2021-01-26
EP3473642A2 (en) 2019-04-24
EP2970385B1 (en) 2018-10-03
ES2703110T3 (es) 2019-03-07
KR20160012992A (ko) 2016-02-03
EP2970385A1 (en) 2016-01-20
JP2016512205A (ja) 2016-04-25
JP7075918B2 (ja) 2022-05-26
BR112015022469A2 (pt) 2017-07-18
MX2015012038A (es) 2016-06-02
US20200347106A1 (en) 2020-11-05
RU2015143655A3 (pt) 2018-02-28
RU2015143655A (ru) 2017-04-26
US20160039877A1 (en) 2016-02-11
IL241383B (en) 2021-03-25
US20170002049A1 (en) 2017-01-05
US9738695B2 (en) 2017-08-22
US20150203538A1 (en) 2015-07-23
AU2018241212A1 (en) 2018-11-29
CA2906240A1 (en) 2014-09-18
WO2014139472A1 (en) 2014-09-18
US20190023755A1 (en) 2019-01-24
NZ711958A (en) 2020-07-31
JP2020062028A (ja) 2020-04-23
JP6674258B2 (ja) 2020-04-01
EP3473642A3 (en) 2019-07-10
US9388215B2 (en) 2016-07-12
US20180009861A1 (en) 2018-01-11
IL241383A0 (en) 2015-11-30
WO2014139182A1 (en) 2014-09-18
EP3473642B1 (en) 2022-04-13
AU2020280993A1 (en) 2021-01-07
MX2019009886A (es) 2019-10-22
AU2018241212B2 (en) 2020-09-17
EP2970385A4 (en) 2016-12-07
AU2020280993B2 (en) 2022-04-21
AU2014231444B2 (en) 2018-07-19
CA2906240C (en) 2022-10-18

Similar Documents

Publication Publication Date Title
IL285780A (en) Preparations of tmprss6 irna and methods of using them
IL283012A (en) Sustained release formulations of linclotide
IL241383B (en) Compositions and methods for use of peptide islands that have undergone neogenesis and their analogs
HK1217968A1 (zh) 用於 的修飾的方法和組合物
IL245550A0 (en) Preparations and methods for using transposons
ZA201602948B (en) Compositions comprising a defined microbiome and methods of use thereof
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
SG11201506876XA (en) Modification of polypeptides
HK1221416A1 (zh) 氧雜雙環庚烷和氧雜雙環庚烯的配製品
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
SG11201603115YA (en) Conjugates of somatostatin and its analogs
EP2984164A4 (en) COMPOSITIONS FOR CELL RESTORATION AND METHODS OF MAKING AND USING THEM
PL2991618T3 (pl) Stabilna kompozycja farmaceutyczna o wysokim stężeniu lewoleukoworyny
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
PL3063152T3 (pl) Dogodne wytwarzanie n-podstawionych morfinan-6-oli z morfinan-6-onów
GB2533036B (en) Methods of cementing lassenite-containing cement compositions
IL244537A0 (en) New administration preparations and methods of their use
IL248433A0 (en) Stable compounds of neuroactive peptides
KR102216470B9 (ko) 천연물 조성물
PL3071575T3 (pl) Wytwarzanie normorfinanów
GB201315461D0 (en) Composition of phosphonates